Is LABT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LABT. It does not provide personalized investment advice.

LABT (Lakewood-Amedex Biotherapeutics Inc. Common Stock) Stock Analysis - Financials

Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) is a publicly traded the market company. As of July 7, 2026, LABT trades at $2.70 with a market cap of $4.81M and a P/E ratio of 0.00. LABT moved +0.00% today. Year to date, LABT is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $2.41 to $98.20. Rallies surfaces LABT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are LABT's key financials?

LABT financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. LABT recently traded at $2.70. Market cap is $4.81M. P/E ratio is 0.00. Revenue is $0.

LABT Key Metrics

Key financial metrics for LABT
Metric	Value
Price	$2.70
Market Cap	$4.81M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$98.20
52-Week Low	$2.41
Volume	44.71K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

LABT Analyst Consensus

LABT analyst coverage data. Average price target: $0.00.

Common questions about LABT

What are LABT's key financials?: LABT financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. LABT recently traded at $2.70. Market cap is $4.81M. P/E ratio is 0.00. Revenue is $0.
Is LABT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LABT. It does not provide personalized investment advice.